FCγRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus

European Cytokine Network

Volumn 10, Issue 4, 1999, Pages 509-513

  Batteux, Frédéric ^a   Palmer, Pierre ^a   Daëron, Marc ^b   Weill, Bernard ^c   Lebon, Pierre ^a,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT CURIE   (France)

^c Hôpital Cochin AP HP ^*  (France)

^d HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

CD32; Fc receptor; Interferon; Systemic lupus erythematosus; Viral immune complexes

Indexed keywords

ALPHA INTERFERON; ANTIBODY; CD32 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G; AUTOANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; PLASMA PROTEIN;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS INFECTION; BIOLOGICAL MODEL; BIOSYNTHESIS; BLOOD; CELL CULTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; GEL CHROMATOGRAPHY; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PH; PHYSIOLOGY; SOLUBILITY;

ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BLOOD PROTEINS; CELLS, CULTURED; CHROMATOGRAPHY, GEL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, IMMUNOLOGICAL; RECEPTORS, IGG; SOLUBILITY;

EID: 0032586001     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. 1. Spronk P E, Limburg P C, Kallenberg C G. 1995. Serological markers of disease in systemic lupus erythematosus. (Review) Lupus 4: 86.
2. 2. Preble O T, Black R J, Friedman R M, Klippel J H, Vilcek J. 1982. Systemic Lupus Erythematosus: presence of an unusual acide-labile leukocyte interferon. Science 216: 429.
3. 3. Hooks J J, Motsoupoulos H M, Geis S A, Stahl N I, Deker J L, Notkins A L. 1979. Immune interferon in the circulation of patients with autoimmune diseases. N. Engl. J. Med. 301: 5.
4. 4. Ytterberg S R, Schnitzer T J. 1982. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis. Rheum. 25: 401.
5. 5. Lebon P, Lenoir G R, Fischer A, Lagrue A. 1983. Synthesis of intrathecal interferon in systemic lupus erythematosus with neurological complications. Brit. Med. J. 287: 1165.
6. 6. Rich S A. 1981. Human lupus inclusions and interferon. Science 213: 772.
7. 7. Tolaymat A, Leventhal B, Sakarcan A, Kashima H, Monteiro C. 1992. Systemic lupus erythematosus in a child receiving long term interferon therapy. J. Pediatr. 120: 429.
8. 8. Morris L F, Lemak N A, Arnett F C Jr, Jordon R E, Duvic M. 1996. Systemic lupus erythematosus diagnosed during interferon alpha therapy. (Review) South. Med. J. 89: 810.
9. 9. Garcia-Porrua C, Gonzales-Gay M A, Fernandez-Lamelo F, Paz-Carreira J M, Lavilla E, Gonzalez-Lopez M A. 1998. Simultaneous development of SLE-like syndrome and autoimmune thyroiditis following alpha-interferon treatment. (letter) Clin. Exp. Rheumatol. 16: 107.
10. 10. O'Garra A, Murphy K. 1996. Role of cytokines in developement of th1 and th2 cells In: Romagni ed. Th1 and Th2 cells in health and diseases. Chem. Immunol. 63: 1.
11. 11. Lebon P. 1985. Inhibition of herpes simplex virus type 1-induced interferon synthesis by monoclonal antibodies against viral glycoprotein D and by lysosomotropic drugs. J. Gen. Virol. 66: 2781.
12. 12. Ankel H, Westra D F, Wellin-Wester S, Lebon P. 1998. Induction of interferon-α by glycoprotein D of herpes simplex virus: a possible role of chemokine receptors. Virology 251: 317.
13. 13. Fitzgerald-Bocarsly P. 1993. Human natural interferon producing cells. (Review) Pharmac. Ther. 60: 39.
14. 14. Ito Y, Bando H, Komada H, Tsurudome M, Nishio M, Kawano M, Matsura H, Kusagawa S, Yusaa T, Ohta H. 1994. HN proteins of human parainfluenza type 4-A virus expressed in cell lines transfected with a cloned cDNA have an ability to induce interferon in mouse spleen cells. J. Gen. Virol. 75: 567.
15. 15. Ankel H, Capobianchi M, Frezza F, Castilletti C, Dianzani F. 1996. Interferon induction by HIV-infected cells: a possible role of sulfatides or related glycolipids. Virology 221: 113.
16. 16. Francis ML, Meltzer M S. 1993. Induction of IFN-α by HIV-1 in monocyte-enriched PBMC requires gp120-CD4 interaction but not virus replication. J. Immunol. 151: 2208.
17. 17. Baudoux P, Carrat C, Besnardeau L, Charley B, Laude H. 1998. Coronavirus pseudo-particles formed with recombinant M and E proteins induce alpha interferon synthesis by leucocytes. J. Virol. 72: 8636.
18. 18. Cederblad B, Blomberg S, Vallin V, Perers A, Alm G V, Rönnblom L. 1998. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha producing cells. J. Autoimmun. 11: 465.
19. 19. Vallin H, Blomberg S, Alm G V, Cederblad B, Rönnblom L. 1999. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-α production acting on leukocytes resembling immature dendritic cells. Clin. Exp. Immunol. 115: 196.
20. 20. Lebon P, Charley B, Daëron M, Cao L, Cohen J. 1995. FCγRII CD32 is involved in the induction of alpha interferon by viruses complexed with antibodies J. Interfer. Res. 15 (Suppl 1): 208.
21. 21. Bombardier C, Gladman D D, Urowitz M B, Caron D, Chang C H. 1992. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthitis. Rheum. 35: 630.
22. 22. Gresser I, Bandu M T, Brouty-Boyé D, Tovey M. 1974. Pronounced antiviral activity of human interferon on bovine and porcine cells. Nature 251: 543.
23. 23. Adolf G R, Frühbeis B, Hauptmann R, Kalsner I, Maurer-Froy I, Ostmann E, Patzelt E, Schwendenwein R, Sommergruber W, Zophel A. 1991. Human interferon ω1: isolation of the gene, expression in Chinese hamster ovary cells and characterisation of the recombinant protein. Biochem. Biophys. Acta. 1089: 167.
24. 24. Looney R J, Abraham G N, Anderson C L. 1986. Human monocytes and U937 bear two distinct Fc Receptors for IgG. J. Immunol. 136: 1641.
25. 25. Greenman J, Tutt A L, George A J, Pulford K A, Stevenson G T, Glennie M J. 1991. Characterization of new monoclonal anti FcγRII antibody, AT10, and its incorporation into a bispecific F(ab')2 derivative for recruitment of cytotoxic effectors. Mol. Immunol. 28: 1243.
26. 26. Daëron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, Fridman W H. 1995. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR dependent cell activation. Immunity 3: 635.
27. 27. Daëron M. 1997. Fc receptor biology. (Review) Annu. Rev. Immunol. 15: 203.
28. 28. Yee A M, Buyon J P, Yip Y K. 1989. Interferon alpha associated with systemic lupus erythematosus is not intrinsically acid labile. J. Exp. Med. 169: 987.
29. 29. Duits A J, Bootsma H, Derksen H, Spronk P E, Kater L, Kallenberg C G, Capel P J, Westerdaal N A, Spierenburg G T, Gmelig-Meyling F H, et al. 1995. Skewed distribution of IgG Fc receptor II a (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patient. Arthritis. Rheum. 38: 1832.
30. 30. Salmon J E, Millard S, Schachter L A, Arnett F C, Ginzler E M, Gourley M F, Ramsey-Goldman R, Petterson M G, Kimberley R P. 1996. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J. Clin. Invest. 97: 1348.
31. 31. Zack D J, Stempniak M, Wong A L, Taylor C, Weisbart R H. 1996. Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody. J. Immunol. 157: 2082.
32. 32. Avrameas A, Ternynck T, Nato F, Buttin G, Avrameas S. 1998. Polyreactive anti-DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic and intranuclear translocation of macromolecules. Proc. Natl. Acad. Sci. USA 95: 5601.
33. 33. Heremans H, Billiau A, Colombatti A, Hilgers J, De Somerc P. 1978. Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect. Immunol. 21: 925.
34. 34. Sergiescu D, Cerutti I, Effthymiou E, Kahan A, Chany C. 1979. Adverse effects of interferon treatment on the life span of NZB mice. Biomedecine 31: 48.
35. 35. Adam C, Thoua Y, Ronco P, Verroust P, Tovey M, Morel-Maroger L. 1980. The effect of exogenous interferon: acceleration of autoimmune and renal diseases in NZB/W F1 mice. Clin. Exp. Immunol. 40: 373.
36. 36. Gresser I, Morel-Maroger L, Riviere Y, Guillon J C, Tovey M G, Woodrow D, Sloper J C, Moss J. 1980. Interferon-induced disease in mice and rats. Ann. NY. Acad. Sci. 350: 12.